Company Analysis
Sign in

Nuvation Bio Inc. (NUVB)

NYSE: NUVB · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2020
Full chart Alerts Compare
Grade5.4
◀ Past 6.2● Present 4.6▶ Future 5.8
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

17 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Nuvation Bio Inc.’s names, not what it holds today.

Patents granted
17
17 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 2 in 2024 and 3 in 2023
Applications published
37
2 of them in 2025
Names they are printed under
3
its own name, a subsidiary
By yearGrantedApplications published
'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Organic fine chemistry12
Pharmaceuticals3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
Nuvation Bio Inc. its own name
named as the applicant on its applications, in US
0 granted
35 published
NUVATION BIO INC. its own name
US, as the owner printed on each patent. 1 more under the same name are not counted (printed in BM)
17 granted
1 published
Nuvation Bio Operating Company Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Aug 26, 202512,398,121Anti-cancer nuclear hormone receptor-targeting compoundsOrganic fine chemistryNUVATION BIO INC.
Jan 28, 202512,208,141Anti-cancer nuclear hormone receptor-targeting compoundsPharmaceuticalsNUVATION BIO INC.
Jun 11, 202412,006,314Anti-cancer nuclear hormone receptor-targeting compoundsOrganic fine chemistryNUVATION BIO INC.
Apr 9, 202411,952,349Anti-cancer nuclear hormone receptor-targeting compoundsOrganic fine chemistryNUVATION BIO INC.
Dec 5, 202311,834,458Anti-cancer nuclear hormone receptor-targeting compoundsOrganic fine chemistryNUVATION BIO INC.
Nov 28, 202311,826,430Anti-cancer nuclear hormone receptor-targeting compoundsPharmaceuticalsNUVATION BIO INC.
Feb 21, 202311,584,756Heterocyclic compounds as BET inhibitorsOrganic fine chemistryNUVATION BIO INC.
May 17, 202211,332,473Substituted pyrazolo[3,4-d]pyrimidines as Wee1 inhibitorsPharmaceuticalsNUVATION BIO INC.
Apr 19, 202211,306,071Heterocyclic compounds as adenosine antagonistsOrganic fine chemistryNUVATION BIO INC.
Apr 12, 202211,299,493Heterocyclic compounds and uses thereofOrganic fine chemistryNUVATION BIO INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 23, 20252025/0326756METHOD FOR PRODUCING 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDSOrganic fine chemistryNuvation Bio Inc.
Sep 4, 20252025/0276978HETEROCYCLIC COMPOUNDS AS BET INHIBITORSOrganic fine chemistryNuvation Bio Inc.
Oct 24, 20242024/0352027ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDSOrganic fine chemistryNuvation Bio Inc.
Jun 6, 20242024/0181066ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDSPharmaceuticalsNuvation Bio Inc. · patent 12,208,141 granted from it
Oct 26, 20232023/0339964HETEROCYCLIC COMPOUNDS AS BET INHIBITORSOrganic fine chemistryNuvation Bio Inc.
Jun 8, 20232023/0174545HETEROCYCLIC COMPOUNDS AS BET INHIBITORSPharmaceuticalsNuvation Bio Inc.
Apr 20, 20232023/0122310ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDSOrganic fine chemistryNuvation Bio Inc. · patent 12,398,121 granted from it
Apr 20, 20232023/0118115SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS WEE1 INHIBITORSPharmaceuticalsNuvation Bio Inc.
Apr 6, 20232023/0109104HETEROCYCLIC COMPOUNDS AND USES THEREOFOrganic fine chemistryNuvation Bio Inc.
Mar 2, 20232023/0066315COMPOUNDS AND USES THEREOFOrganic fine chemistryNuvation Bio Inc.
What it applied for, 2024 to 2025: Organic fine chemistry 3 · Pharmaceuticals 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton NUVB · research, not advice